LON:HVO hVIVO (HVO) Share Price, News & Analysis GBX 6.40 -0.20 (-3.03%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About hVIVO Stock (LON:HVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get hVIVO alerts:Sign Up Key Stats Today's Range 6.32▼ 6.6050-Day Range 6.43▼ 7.7552-Week Range 4.31▼ 11Volume3.08 million shsAverage Volume2.54 million shsMarket Capitalization£44.06 millionP/E RatioN/ADividend Yield2.68%Price TargetGBX 15Consensus RatingModerate Buy Company Overview hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. Read More Receive HVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for hVIVO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HVO Stock News HeadlineshVIVO to Report Interim Results on 15 SeptemberSeptember 4, 2026 | uk.finance.yahoo.comhVIVO (LON:HVO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?September 4, 2026 | americanbankingnews.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.September 14 at 1:00 AM | Porter & Company (Ad)hVIVO plc: hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health marketsAugust 27, 2026 | finanznachrichten.dehVIVO buys Berlin trials unit for token upfront sumAugust 27, 2026 | uk.finance.yahoo.comhVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health marketsAugust 27, 2026 | markets.ft.comhVIVO, Rome Resources, Arrow Exploration, Bradda Head, Sintana Energy, Light Science TechnologiesAugust 27, 2026 | finance.yahoo.comhVIVO CEO sees strong H2 2026 revenue outlook as development platform expands - ICYMIJuly 25, 2026 | uk.finance.yahoo.comSee More Headlines HVO Stock Analysis - Frequently Asked Questions How have HVO shares performed this year? hVIVO's stock was trading at GBX 6.10 on January 1st, 2026. Since then, HVO stock has increased by 4.9% and is now trading at GBX 6.40. How were hVIVO's earnings last quarter? hVIVO plc (LON:HVO) posted its quarterly earnings data on Wednesday, April, 15th. The company reported ($0.87) earnings per share for the quarter. The business had revenue of $46.77 million for the quarter. hVIVO had a negative trailing twelve-month return on equity of 14.65% and a negative net margin of 12.48%. How do I buy shares of hVIVO? Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of hVIVO own? Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR). Company Calendar Last Earnings4/15/2026Today9/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:HVO Previous SymbolLON:RVG CIKN/A Webhvivo.com Phone+44-20-77561300FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for hVIVOGBX 15 High Price TargetGBX 25 Low Price TargetGBX 10 Potential Upside/Downside+134.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.87) Trailing P/E RatioN/A Forward P/E Ratio4.13 P/E GrowthN/ANet Income£17.84 million Net Margins-12.48% Pretax MarginN/A Return on Equity-14.65% Return on Assets11.97% Debt Debt-to-Equity Ratio38.75 Current Ratio1.63 Quick Ratio1.16 Sales & Book Value Annual Sales£46.77 million Price / Sales0.94 Cash FlowGBX 1.30 per share Price / Cash Flow4.94 Book ValueGBX 5.56 per share Price / Book1.15Miscellaneous Outstanding Shares688,401,000Free FloatN/AMarket Cap£44.06 million OptionableNot Optionable Beta1.69 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:HVO) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | SponsoredElon Musk Predicts This Will be the Next Wave of AINvidia CEO Jensen Huang says the Accelerated AI inflection has arrived. Elon Musk has predicted that 99 percen...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
